Drawing for SCANCELL

USPTO serial 88486481

SCANCELL

Reviewed by CopyMark Law Group

Reg. 5994748Status 704Registered
Filing date
Status date
Registration date
Feb 25, 2020
Examiner
MAHONEY, PAULA M
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 704 applies to Madrid Protocol extensions of protection in the U.S. Section 71 (similar to Section 8) showing continued use was accepted. The U.S. extension remains active. Follow Madrid and USPTO deadlines for the next renewal cycle.

Status 704: Status 704 applies to Madrid Protocol extensions of protection in the U.S. Section 71 (similar to Section 8) showing continued use was accepted. The U.S. extension remains active.

Need help with SCANCELL?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Andrew D. Price

Andrew D. Price VENABLE LLPP.O. Box 34385Washington, DC 20043-9998United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations, namely, for the treatment of cancer; therapeutic preparations and substances, namely, for the treatment of cancer; chemical preparations, namely, for the treatment of cancer; diagnostic reagents for medical use; DNA, antibodies and proteins that stimulate high-avidity T-cells responses for therapeutic and medical use, namely, for the treatment of cancer; pharmaceutical compounds for treatment of cancer; vaccine preparations and substances; peptide vaccines; DNA vaccines and substances; Therapeutic preparations and substances for medical use, namely, DNA, antibodies and proteins for use in expressing epitopes, for use in encoding, for use in vectoring to target cells, and for use in stimulating cells; vaccines, including DNA vaccines; Therapeutic preparations for use in T-cell therapy and chimeric antigen receptor T-cell therapy to treat cancerACTIVE—
042[ Pharmaceutical testing and clinical trials for others; provision of information and consultancy in relation to the aforesaid services; scientific and technological services, namely, research and design in the field of drug development for the treatment of cancer; pharmaceutical research and development services; research and development in the biotechnology field; provision of information and consultancy in relation to the aforesaid services ]SECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 20, 2026NAS8NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED—
Oct 20, 20268.PRREGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED—
Oct 19, 2026APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Aug 25, 2026ES8RTEAS SECTION 8 RECEIVED—
Feb 25, 2025REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Jan 19, 2023CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Jan 19, 2023TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jan 19, 2023ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Jan 19, 2023ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 19, 2023REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jan 19, 2023COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Feb 25, 2020R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 10, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 10, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 20, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 4, 2019PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Nov 3, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 30, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 30, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 28, 2019ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Sep 14, 2019GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Sep 14, 2019GNSLLETTER OF SUSPENSION E-MAILED—
Sep 14, 2019CNSLSUSPENSION LETTER WRITTEN—
Sep 13, 2019DOCKASSIGNED TO EXAMINER—
Aug 13, 2019AMPXPRELIMINARY/VOLUNTARY AMENDMENT - ENTERED—
Aug 8, 2019ALIEASSIGNED TO LIE—
Aug 1, 2019TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Aug 1, 2019PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Jul 3, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 27, 2019NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance